Animal Health Products

Taking advantage of our new pesticide discovery technology that we have fostered so far, we have developed (fuzapladib), an anti-pancreatitis drug for dogs.
We provide excellent products that the owners of companion animals and animal healthcare professionals depend on.


  1. Strength 1
    Development, manufacture, and sales that integrate the various functions of R&D, marketing, and pharmaceutical regulatory affairs management
  2. Strength 2
    Access to a global market centered on the U.S. and Europe
  3. Strength 3
    Able to develop related products for product lifecycle management; a wealth of seed ideas for new product developmen

Typical Applications

  • Anti-inflammatory drug for acute phase of pancreatitis in dogs

Fuzapladib Sodium Hydrate

In September 2018, we obtained manufacturing/marketing approval for this drug with the effect of “improvement of clinical signs in the acute phase of pancreatitis in dogs”.
Fuzapladib blocks activation of adhesion molecules (integrin) expressed on the inflammatory cell surface to prevent inflammatory cells from adhering to vascular endothelial cells and infiltrating tissue and to control exacerbation of pancreatitis.
This mode of action is different from that of conventional anti-inflammatory drugs including steroids and non-steroid anti-inflammatory drugs (NSAIDs).
No veterinary drugs with a similar action mechanism is available anywhere in the world, including Japan.

Figure: Fuzapladib Sodium Hydrate

*You can see the entire image in the figure by scrolling horizontally.

IUPAC name N-[2-(ethylsulfonylamino)-5-(trifluoromethyl)-3-pyridinyl]cyclohexanecarboxamide mono sodium salt monohydrate
Molecular weight 419.40
Molecular formula C15H19F3N3NaO3S・H2O
CAS RN 351999-87-6
Development code IKV-741, IS-741, SH-741

Fuzapladib sodium hydrate is the active pharmaceutical ingredient in ISK’s animal health product, BRENDATM, which ISK manufactures and distributes in Japan. ISK also supplies fuzapladib sodium hydrate to Nippon Zenyaku Kogyo Co., LTD as drug substance for BRENDATMZ.

PanoquellTM-CA1, which uses this active ingredient, received conditional approval from the FDA in November 2022. Its sales in the United States began in April 2023.
Furthermore, through our partnership with Ceva, a world’s leading veterinary pharmaceutical company, we aim to promote the PanoquellTM brand throughout the world, including Europe.

Use of cookies

This website uses cookies to provide more convenience for you. Please consent to the use of cookies when viewing this website. If you continue to browse this website, we will assume that you agree to the use of cookies.
For more information